Salute e Benessere

ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care…

A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website,ir.adctherapeutics.com. A replay of the webcast will be available for approximately 30 days. About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for...

Sleeping Bag Market Size to Surpass Around US$ 2.79 Billion 2030, Recording a…

The increasing popularity of camping and outdoor activities is one of the major drivers for the growth of the sleeping bag market. With the rising interest in adventure sports and recreational activities, more individuals are opting for camping trips and outdoor adventures. This has led to a significant increase in the demand for sleeping bags, as they are essential for providing comfort and warmth during outdoor stays. Moreover, the growing trend of off-grid vacations and sustainable tourism is…

Philips launches new Azurion neuro biplane system at #ECR2024 to speed up and…

New image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseasesAmsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced major enhancements to its Image Guided Therapy System – Azurion – with the launch of its new Azurion neuro biplane system . Designed to streamline neurovascular procedures...

Zymeworks Announces Participation in Upcoming Investor Conferences

TD Cowen 44 thAnnual Health Care Conference: Zymeworks' management will participate in one-on-one meetings and present on March 6 that 11:10 am Eastern Time (ET) in Boston, MA.Barclays 26 thAnnual Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on March 14 that 11:45 am ET in Miami, FL. All presentations and webcasts will be available on Zymeworks' website athttp://ir.zymeworks.com/events-and-presentations...

Smiles for All: Singapore Dental Services Market Shines Bright at 5.8% CAGR…

Several key factors are propelling the Singaporean dental services market towards a promising future: Several key factors are propelling the Singaporean dental services market towards a promising future: Interested to Know More about this Report, Request a Free Sample Report Segmentation Spotlight: Ken Research provides a detailed segmentation of the market, allowing you to pinpoint your target audience effectively: Competitive Landscape: The Singaporean dental...

New Models of PENTAX Medical i20c Video Endoscope Series Obtain CE Marks

In combination with PENTAX Medical INSPIRA™ Video Processor EPK-i8020c, the PENTAX Medical i20c Video Endoscope Series aim to support healthcare professionals in detection, diagnosis and therapy better than ever. Physicians can instantly benefit from uncompromising vision and scope maneuverability. In combination with PENTAX Medical INSPIRA™ Video Processor EPK-i8020c, the PENTAX Medical i20c Video Endoscope Series aim to support healthcare professionals in detection, diagnosis and therapy...

Affidea successfully reprices its debt and raises an additional €200 million…

Affidea is constantly considering a number of bolt-on acquisitions to enhance its local scale and service diversification in order to better address the needs of its patients and doctors in every community. The new credit facility comes to support the company in pursuing its expansion plans for the next years. Affidea is constantly considering a number of bolt-on acquisitions to enhance its local scale and service diversification in order to better address the needs of its patients and…

"Barbora Polska" ceases operations in Poland

"Barbora Polska" Sp. z o. o., providing home food delivery service in Tricity, Warsaw, Katowice, and Lodz in Poland, is ceasing its operations. It is planned that "Barbora" services will be provided until March 3 . According to the statement of Viktoras Juozapaitis, the director of RADAS, UAB, which controls the company “Barbora Polska“, the decision was influenced by the slowly growing demand: "In response to the sharply increased demand for home food delivery during…

Crossject obtains a financing up to €12 million, in two tranches

Crossject obtains a financing up to €12 million, in two tranches, from an entity managed by Heights Capital Management, in issued bonds convertible in new shares, with a conversion premium of 35% 1, or repayable (in cash and/or stocks, according to the company's options) over 36 months at a rate of 7% 2.CROSSJECT (ISIN: FR0011716265; Stock symbol: ALCJ), a specialty pharma company developing needle-free auto-injectors for emergency situations,, announces today the issue,...

ZINZINO AB (PUBL): YEAR END REPORT 2023

Revenues during the fourth quarter of 2023 amounted to SEK 527.9 (429.3) million, which corresponded to 23% (7%) growth compared to the corresponding period last year. The EBITDA result increased to SEK 71.3 (40.8) million and the EBITDA margin to 13.5% (9.5%). As before, behind the margin improvement are primarily changes in the sales mix, efficiencies and economies of scale. During the quarter, the company changed Certified Adviser to Carnegie Investment Bank AB and introduced a new customer…

Systemair's Interim Report for the third quarter will be presented on March 5

To participate in the webcast: To participate in the webcast: If you would like to participate in the webcast, please register via the link below. After registration, you will receive a link to confirm your email. There will be an opportunity to ask questions at any time during the presentation by submitting a written question via webcast. https://www.investis-live.com/systemair/65b251d47f77220c00db94d1/jsre If you wish to participate by phone, see details below: Sweden : +46...

Mendus to participate in upcoming industry conferences

Press release Stockholm, Sweden, February 27, 2024Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, today announced that it will participate in the following upcoming industry conferences: 10th annual IO360° SummitNew York, USA, February 27-29, 2024CEO Erik Manting will participate in the 10th annual IO360° Summit, a conference dedicated to reporting on the latest advancements and data in...

NEXSTIM PLC'S FINANCIAL STATEMENTS BULLETIN 2023

Company announcement, Helsinki 27 February 2024 at 9 am (EET)NEXSTIM PLC'S FINANCIAL STATEMENTS BULLETIN 2023NEXSTIM CONTINUED TO GROW COMPARABLE NET SALES WITH A RECORD YEAR-END July–December 2023The company's net sales were EUR 4.7 million (2.7), with an increase of 73.5%Comparable net sales increased by 73.5%, to EUR 4.7 million (2.7)EBITDA was EUR 0.6 million (-1.2)The operating result was EUR 0.2 million (-1.5)The profit for the period was EUR 0.1 million (-1...

Zealand Pharma convenes its Annual General Meeting 2024

Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no. 20 04 50 78) (the "Company"). The Board of Directors of the Company hereby convenes the Annual General Meeting of the Company to be held on: Wednesday, March 20, 2024 at 3:00 pm (CEST) The Annual General Meeting will be held as a partly electronic general meeting with the possibility of attending electronically or in...

Zealand Pharma Announces Financial Results for the Full Year 2023

Company announcement - No. 9 / 2024 Zealand Pharma Announces Financial Results for the Full Year 2023Significant progress delivered across our obesity and rare disease assets while building a solid financial positionPositive results achieved for petrelintide in 6-week Phase 1 trial and clinical advancement of dapiglutide and petrelintide towards obesity data readouts in 2024Positive results announced in Boehringer Ingelheim Phase 2 clinical trials for survodutide in obesity and...

Trademark WALOVI Made Its Debut Globally to Share the Chinese Herbal Tea Culture…

Weng Shaoquan, Chairman of the Board of Guangzhou Wanglaoji Great Health Industry Co., Ltd., commented, "Not only do we need to offer good products, but we also need to spread the traditional Chinese herbal tea culture and the culture of Ji (good fortune) to the world, and convey the brand concept of 'bringing good fortune to the world'. By doing that, we can transform from a national brand to an international one and thus continue to carry forward the exchanges between the herbal tea…

Curve Therapeutics raises £40.5 million to turbocharge discovery platform and…

Simon Kerry, PhD, MBA, Chief Executive Officer of Curve Therapeutics, said: "This financing will enable us to expand our team, progress our lead assets into the clinic and to expand our drug discovery platform. We welcome our new investors alongside our existing strong syndicate and look forward to working together to take Curve to its next stage of growth." Simon Kerry, PhD, MBA, Chief Executive Officer of Curve Therapeutics, said: "This financing will enable us to expand our…

OMANI HIGH PERFUMERY HOUSE AMOUAGE OPENS ITS FIRST POP UP BOUTIQUE IN CHINA

The pop-up construction features the elements of the brutalist style developed by Renaud Salmon, Chief Creative Officer, sees burnt cork, travertine and sandstone elements with radiating luminosity to reflect the heritage and sensations of the Sultanate of Oman, highlighting the perfume creations introduced in the past years. The pop-up construction features the elements of the brutalist style developed byRenaud Salmon, Chief Creative Officer, sees burnt cork, travertine and sandstone...

U.S. FDA Accepts for Priority Review the Supplemental Biologics License…

Media Release COPENHAGEN, Denmark; February 27, 2024 FDA grants Priority Review with target action date of June 28, 2024Application based on results from Phase 1/2 EPCORE™ NHL-1 trial demonstrating clinically meaningful treatment responses in difficult-to-treat patients with relapsed or refractory (R/R) follicular lymphoma (FL)sBLA submission demonstrates Genmab's commitment to exploring potential utility of epcoritamab across B-cell malignancies Genmab A/S(Nasdaq:...

Telix Expands U.S. Development and Manufacturing Infrastructure with Acquisition…

The acquisition will also expand Telix's U.S. manufacturing footprint with a site that includes a GMP[1] clean room and production infrastructure suitable for clinical use. The site also has extensive capacity to process a wide variety of therapeutic isotopes used in Telix's development portfolio. The acquisition will also expand Telix's U.S. manufacturing footprint with a site that includes a GMP [1]clean room and production infrastructure suitable for clinical use. The site also has...

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged…

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company's liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future. The Company is encouraged by these study results as they confirm the approach the Company is taking with…

Groupe Casino: Paris Commercial Court approves the accelerated safeguard plans…

Paris Commercial Court approves the accelerated safeguard plans for Casino and its subsidiaries Paris, 26 February 2024Casino announces that, by judgments dated 26 February 2024, the Paris Commercial Court, after having acknowledged that all conditions precedent had been satisfied, approved the accelerated safeguard plans for Casino (the “ Company ”) and some of its subsidiaries 1examined during the hearings held on 5 February 2024 and 12 February 2024. The Paris Commercial Court has...

AB Science announces that Health Canada has issued a Notice of…

PRESS RELEASEAB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS ISSUED A NOTICE OF NON-COMPLIANCE-WITHDRAWAL (NON/w) FOR MASITINIB IN AMYOTROPHIC LATERAL SCLEROSISAB SCIENCE INTENDS TO SUBMIT A REQUEST FOR RECONSIDERATIONParis, 26 February, 2024, 6.15pm CETAB Science SA(Euronext - FR0010557264 - AB) today announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral...

Neomorph Announces Multi-Target Collaboration with Novo Nordisk to Discover…

Under the terms of the agreement, Neomorph will receive an upfront and near-term milestone payments, plus R&D funding. Neomorph is also eligible to receive future clinical, commercial and sales milestone payments bringing the total potential deal value for multiple targets to $1.46B, plus tiered royalties. Neomorph will lead discovery and preclinical activities against selected targets with Novo Nordisk having the right to exclusively pursue further clinical development and commercialization…

Altri Comunicati